NPS Looks To Repeat Success At FDA AdCom With Second Orphan Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Endocrinoloigc and Metabolic Drugs Advisory Committee will weigh in on Natpara for hypoparathryodism Sept. 12.